⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NRIX News
Nurix Therapeutics, Inc. Common stock
Nurix Therapeutics to Participate in Upcoming September Investor Conferences
globenewswire.com
NRIX
Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
globenewswire.com
NRIX
Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader
globenewswire.com
NRIX
Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
globenewswire.com
NRIX
Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
globenewswire.com
NRIX
Form 8-K
sec.gov
NRIX
Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com
NRIX
A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs
prnewswire.com
GTBP
XNCR
CTMX
ZYME
NRIX
Form 8-K
sec.gov
NRIX
Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy
globenewswire.com
NRIX